Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trialSanjay Ramakrishnan, Mona Bafadhel, Philippa C. Matthews et al.|The Lancet Respiratory Medicine|2021Cited by 434
Treating eosinophilic exacerbations of asthma and COPD with benralizumab (ABRA): a double-blind, double-dummy, active placebo-controlled randomised trialSanjay Ramakrishnan, Mona Bafadhel, Richard Russell et al.|The Lancet Respiratory Medicine|2024Cited by 98
Blood Eosinophil Depletion with Mepolizumab, Benralizumab, and Prednisolone in Eosinophilic AsthmaAngela Moran, Lauri Lehtimäki, Sanjay Ramakrishnan et al.|American Journal of Respiratory and Critical Care Medicine|2020Cited by 76
Inhaled budesonide in the treatment of early COVID-19 illness: a randomised controlled trialSanjay Ramakrishnan, Mona Bafadhel, Dan V. Nicolau et al.|medRxiv|2021Cited by 25
Inhaled Budesonide in the Treatment of Early COVID-19 Illness: A Randomised Controlled TrialSanjay Ramakrishnan, Mona Bafadhel, Dan V. Nicolau et al.|SSRN Electronic Journal|2021Cited by 5